Novartis Pipeline

Benefiting from our continued focus on innovation, Novartis has one of the industry’s most competitive pipelines. Many of these projects, which include new molecular entities as well as additional indications and different formulations for marketed products, are for medicines that could significantly advance treatment standards for patients worldwide. This table provides an overview of selected projects in development. Please note: the Novartis Pipeline data is updated quarterly.

Download the Novartis Pipeline from the 2023 Annual Report (PDF 0.1 MB)

Show Filters
Showing 105 results
  • AAA601
    Lutathera®
    GEPNET, pediatrics
    Oncology: Solid Tumors Phase 2 Radioligand therapy target SSTR
  • AAA601
    Lutathera®
    Glioblastoma
    Oncology: Solid Tumors Phase 2 Radioligand therapy target SSTR
  • AAA601
    Lutathera®
    1L ES-SCLC
    Oncology: Solid Tumors Phase 2 Radioligand therapy target SSTR
  • AAA601
    Lutathera®
    Gastroenteropancreatic neuroendocrine tumors, 1st line in G2/3 tumors (GEP-NET 1L G3)
    Oncology: Solid Tumors Registration 2024 Radioligand therapy target SSTR
    Supplementary Indication
  • AAA603
    177Lu-NeoB
    Breast cancer
    Oncology: Solid Tumors Phase 1 Radioligand therapy target GRPR
  • AAA603
    177Lu-NeoB
    Glioblastoma multiforme
    Oncology: Solid Tumors Phase 1 Radioligand therapy target GRPR
  • AAA603
    177Lu-NeoB
    Multiple solid tumors
    Oncology: Solid Tumors Phase 2 ≥ 2027 Radioligand therapy target GRPR
    Lead Indication
  • AAA604
    AAA604
    Pancreatic cancer
    Oncology: Solid Tumors Phase 1 Radioligand therapy target integrin beta-3/beta-5
  • AAA614
    AAA614
    Solid tumors
    Oncology: Solid Tumors Phase 2 Radioligand therapy target FAP
    Lead Indication
  • AAA617
    Pluvicto®
    Metastatic hormone sensitive prostate cancer (mHSPC)
    Oncology: Solid Tumors Phase 3 2025 Radioligand therapy target PSMA
  • AAA617
    Pluvicto®
    Oligometastatic prostate cancer
    Oncology: Solid Tumors Phase 3 ≥ 2027
  • AAA617
    Pluvicto®
    Metastatic neuroendocrine prostate cancer
    Oncology: Solid Tumors Phase 1 Radioligand therapy target PSMA
  • AAA617
    Pluvicto®
    Metastatic castration-resistant prostate cancer (mCRPC) pre-taxane
    Oncology: Solid Tumors Registration Radioligand therapy target PSMA
  • AAA802
    225Ac-PSMA-R2
    Prostate cancer
    Oncology: Solid Tumors Phase 1 Radioligand therapy target PSMA
  • AAA817
    225Ac-PSMA-617
    Metastatic castration-resistant prostate cancer
    Oncology: Solid Tumors Phase 1 Radioligand therapy target PSMA
    Lead Indication
  • ABL001
    Scemblix®
    Chronic myeloid leukemia, 2L, pediatrics
    Oncology: Hematology Phase 2 2026 BCR-ABL inhibitor
    New Indication
  • ABL001
    Scemblix®
    Chronic myeloid leukemia, 1st line
    Oncology: Hematology Registration BCR-ABL inhibitor
  • AIN457
    Cosentyx®
    Giant cell arteritis (GCA)
    Immunology Phase 3 2025 IL17A inhibitor (Anti-interleukin-17 monoclonal antibody)
    Supplementary Indication
  • AIN457
    Cosentyx®
    Polymyalgia rheumatica
    Immunology Phase 3 2026 IL17A inhibitor (Anti-interleukin-17 monoclonal antibody)
  • AMG334
    Aimovig®
    Migraine, pediatrics
    In-market Brands and Global Health Phase 3 ≥ 2027 Selective CGRP receptor antagonist
    Supplementary Indication
Legend

Combination abbreviations:
fulv    fulvestrant
tmx    tamoxifen
gsn    goserelin
NSAI  Non-steroidal aromatase inhibitor
Taf     Tafinlar® (dabrafenib)
Mek   Mekinist® (trametinib)

a    EU filing, approved in US.
b    US filing, approved in EU.
c    US filing, submitted in EU.
d    US pending submission, approved in EU
e    EU filing, submitted in US.

Disclaimer

This information was factually accurate on the date it was published. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information on this page as current or accurate after its publication date. For the latest information on the Novartis' pipeline, readers should visit the News and Investors sections of our website. This information constitutes forward-looking statements relating to Novartis AG's business, including express or implied discussions regarding potential new products, potential new indications for existing products, or regarding potential future revenues from any such products. Such forward-looking statements reflect the current views of Novartis AG regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any new products will be approved for sale in any market, or that any new indications will be approved for existing products in any market, or that such products will achieve any particular revenue levels.

In particular, management's expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays or government regulation generally; the Novartis Group's ability to obtain or maintain patent or other proprietary intellectual property protection, including the uncertainties involved in the US litigation process; competition in general; government, industry, and general public pricing and other political pressures; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.